Radiopharm shares surge 15.47% premarket after announcing successful general meeting with all resolutions approved.

Radiopharm surged 15.47% in premarket trading following the announcement that Radiopharm Theranostics Limited secured approval for all proposed resolutions at its General Meeting on December 3, 2025. The successful outcome, which included key corporate governance or strategic initiatives (details unspecified in the summary), signaled strong shareholder alignment and operational progress, likely boosting investor confidence. The premarket rally reflects optimism over the company’s ability to advance its business objectives without material dissent, though further details on the approved resolutions remain pending.